Cassandra C Brooks1, Lisa J Martin2,3,4, Valentina Pilipenko, Hua He2, Grace K LeMasters5, James E Lockey5, David I Bernstein6, Patrick H Ryan3,4, Gurjit K Khurana Hershey1,4, Jocelyn M Biagini Myers1,4. 1. Division of Asthma Research, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 2. Division of Human Genetics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 3. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 4. Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA. 5. Department of Environmental Health, University of Cincinnati, Cincinnati, OH, USA. 6. Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Abstract
OBJECTIVE: We previously reported that children exposed to secondhand smoke (SHS) that carried variants in the NAT1 gene had over two-fold higher hair cotinine levels. Our objective was to determine if NAT1 polymorphisms confer increased risk for developing asthma in children exposed to SHS. METHODS: White participants in the Cincinnati Childhood Allergy and Air Pollution Study (n = 359) were genotyped for 10 NAT1 variants. Smoke exposure was defined by hair cotinine and parental report. Asthma was objectively assessed by spirometry and methacholine challenge. Findings were replicated in the Genomic Control Cohort (n = 638). RESULTS: Significant associations between 5 NAT1 variants and asthma were observed in the CCAAPS exposed group compared to none in the unexposed group. There was a significant interaction between NAT1 rs13253389 and rs4921581 with smoke exposure (p = 0.02, p = 0.01) and hair cotinine level (p = 0.048, p = 0.042). Children wildtype for rs4921581 had increasing asthma risk with increasing hair cotinine level, whereas those carrying the NAT1 minor allele had an increased risk of asthma regardless of cotinine level. In the GCC, 13 NAT1 variants were associated with asthma in the smoke-exposed group, compared to 0 in the unexposed group, demonstrating gene-level replication. CONCLUSIONS: Variation in the NAT1 gene modifies asthma risk in children exposed to secondhand-smoke. To our knowledge, this is the first report of a gene-environment interaction between NAT1 variants, smoke exposure, cotinine levels, and pediatric asthma. NAT1 genotype may have clinical utility as a biomarker of increased asthma risk in children exposed to smoke.
OBJECTIVE: We previously reported that children exposed to secondhand smoke (SHS) that carried variants in the NAT1 gene had over two-fold higher hair cotinine levels. Our objective was to determine if NAT1 polymorphisms confer increased risk for developing asthma in children exposed to SHS. METHODS: White participants in the Cincinnati Childhood Allergy and Air Pollution Study (n = 359) were genotyped for 10 NAT1 variants. Smoke exposure was defined by hair cotinine and parental report. Asthma was objectively assessed by spirometry and methacholine challenge. Findings were replicated in the Genomic Control Cohort (n = 638). RESULTS: Significant associations between 5 NAT1 variants and asthma were observed in the CCAAPS exposed group compared to none in the unexposed group. There was a significant interaction between NAT1 rs13253389 and rs4921581 with smoke exposure (p = 0.02, p = 0.01) and hair cotinine level (p = 0.048, p = 0.042). Children wildtype for rs4921581 had increasing asthma risk with increasing hair cotinine level, whereas those carrying the NAT1 minor allele had an increased risk of asthma regardless of cotinine level. In the GCC, 13 NAT1 variants were associated with asthma in the smoke-exposed group, compared to 0 in the unexposed group, demonstrating gene-level replication. CONCLUSIONS: Variation in the NAT1 gene modifies asthma risk in children exposed to secondhand-smoke. To our knowledge, this is the first report of a gene-environment interaction between NAT1 variants, smoke exposure, cotinine levels, and pediatric asthma. NAT1 genotype may have clinical utility as a biomarker of increased asthma risk in children exposed to smoke.
Authors: H Wikman; S Thiel; B Jäger; P Schmezer; B Spiegelhalder; L Edler; H Dienemann; K Kayser; V Schulz; P Drings; H Bartsch; A Risch Journal: Pharmacogenetics Date: 2001-03
Authors: Harriet Wikman; Päivi Piirilä; Christina Rosenberg; Ritva Luukkonen; Katja Kääriä; Henrik Nordman; Hannu Norppa; Harri Vainio; Ari Hirvonen Journal: Pharmacogenetics Date: 2002-04
Authors: Berran Yucesoy; Grace E Kissling; Victor J Johnson; Zana L Lummus; Denyse Gautrin; André Cartier; Louis-Philippe Boulet; Joaquin Sastre; Santiago Quirce; Susan M Tarlo; Maria-Jesus Cruz; Xavier Munoz; Michael I Luster; David I Bernstein Journal: J Occup Environ Med Date: 2015-12 Impact factor: 2.162
Authors: G K LeMasters; G K Khurana Hershey; U Sivaprasad; L J Martin; V Pilipenko; M B Ericksen; J W Burkle; M A Lindsey; D I Bernstein; J E Lockey; J Gareri; A Lubetsky; G Koren; J M Biagini Myers Journal: Pharmacogenomics J Date: 2014-08-26 Impact factor: 3.550
Authors: Elisabet Johansson; Lisa J Martin; Hua He; Xiaoting Chen; Matthew T Weirauch; John W Kroner; Gurjit K Khurana Hershey; Jocelyn M Biagini Journal: Clin Exp Allergy Date: 2021-02-13 Impact factor: 5.401